Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.

@article{Valkema2006SurvivalAR,
  title={Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.},
  author={Roelf Valkema and Stanislas A Pauwels and Larry K. Kvols and Raffaella Barone and François Jamar and Willem H. Bakker and Dik J. Kwekkeboom and Hakim Bouterfa and Eric P. Krenning},
  journal={Seminars in nuclear medicine},
  year={2006},
  volume={36 2},
  pages={147-56}
}
Because the role of chemotherapy, interferon, or somatostatin analogs as antiproliferative agents is uncertain, currently few treatment options exist for patients with metastatic or inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NET). Fifty-eight patients with somatostatin receptor-positive GEP-NET were treated in a phase I dose-escalating study with cumulative doses of 47 mCi to 886 mCi of the radiolabeled somatostatin analog [(90)Y-DOTA(0),Tyr(3)]-octreotide. At baseline, 47… CONTINUE READING
93 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 93 extracted citations

Similar Papers

Loading similar papers…